| Literature DB >> 34242392 |
Marcella Kaddoura1, David Dingli1, Francis K Buadi1, Martha Q Lacy1, Morie A Gertz1, Angela Dispenzieri1, Prashant Kapoor1, Lisa Hwa1, Amie Fonder1, Miriam Hobbs1, Suzanne Hayman1, John Lust1, Nelson Leung2, Ronald S Go1, Yi Lin1, Wilson Gonsalves1, Taxiarchis Kourelis1, Rahma Warsame1, Robert A Kyle1, Stephen M Broski3, Vincent Rajkumar1, Shaji Kumar1.
Abstract
Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. We sought to corroborate these findings by examining the prognostic impact of PET/CT scanning in the posttransplant setting. We retrospectively analyzed PET/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET/CT scan findings as an independent prognostic factor. The median OS for the entire cohort was 61.5 months (95% confidence interval [CI], 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). Among patients with abnormal day 100 PET findings (PET+), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET-) (P < .0001). The median OS in the PET+ group was 46 months compared with 99 months in the PET- group (P < .0001). We conclude that an abnormal PET/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34242392 PMCID： PMC8288674 DOI： 10.1182/bloodadvances.2020004131
Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529